Nanochip could spot lymphoma relapse early
NCT ID NCT03656835
First seen Dec 10, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests a new nanochip technology to see if it can better monitor how well treatment is working and detect if lymphoma comes back in people with diffuse large B-cell lymphoma. About 73 participants will provide blood samples during their standard chemotherapy. The goal is to find genetic markers that could help doctors personalize care and catch relapse sooner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.